NTRB and NTRBW Related Headlines
Go Back- Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
- Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
- Nutriband selects brand name for abuse deterrent fentanyl patch
- Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband receives Costa Rica approval for kinesiology tapes
- Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
- Nutriband adds two directors and provides development update
- Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
- Nutriband CEO issues year-end letter highlighting 2025 achievements
- Nutriband CEO Publishes Letter to Shareholders
- Nutriband sells majority stake in subsidiary for $5M to EarthVision Bio
- Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
- Nutriband signs letter of intent with Qvanta Group for tech collaboration
- Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
- Nutriband responds to fentanyl weapon of mass destruction designation
- Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
- Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
- REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband receives FDA feedback on abuse deterrent fentanyl patch
- Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband co-founder Gareth Sheridan returns as CEO
- Nutriband Co-Founder Gareth Sheridan Returns as CEO
- Nutriband partners with Brand Institute for fentanyl patch naming
- Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband files provisional patent for enhanced abuse deterrent technology
- Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
- Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
- Nutriband Inc. to Present at the MicroCap Rodeo Conference
- Nutriband reports 50.87% revenue increase in first half of 2025
- Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
- Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
- Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
- FDA approves meeting request for Nutriband's fentanyl patch development
- FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
- Nutriband sets dates for 25% preferred stock dividend
- Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
- Nutriband (NTRB) Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
- Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
- Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
NTRB and NTRBW Related Press Releases
Go Back- Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
- Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
- Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
- Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
- Nutriband CEO Publishes Letter to Shareholders
- Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
- Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration
- Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
- Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference
- REPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
- Nutriband Co-Founder Gareth Sheridan Returns as CEO
- Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
- Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology
- Nutriband To Present at the Noble Capital Markets’ Emerging Growth Virtual Equity Conference
- Nutriband Inc. to Present at the MicroCap Rodeo Conference
- Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
- Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000
- Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
- FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
- Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval
- Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval
- Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
